Further along these lines, Su et al. recently advocated for an IL-15 antagonist as a therapeutic agent in Stevens-Johnson syndrome and toxic epidermal necrolysis, which are life-threatening immune-related adverse drug reactions mediated by cytotoxic T lymphocytes and NK cells where IL-15 has been shown to be elevated and correlated with the progression and fatality of these severe hypersensitivity reactions (32). Here, IL15 is linked to Stevens-Johnson syndrome.